You should be re-directed to the full story momentarily. If not, please visit https://physician-news.umiamihealth.org/sylvester-study-of-targeted-therapy-for-lung-cancer-contributed-to-fda-approval/.
Introduction Kicker
Sylvester Study of Targeted Therapy for Lung Cancer Contributed to FDA Approval
A patient was diagnosed with non-small cell lung cancer five years ago at age 54. Shortly following the diagnosis, she received news that she carried a rare genetic rearrangement known as a RET fusion in her tumor.
